Back to search

Article

Effectiveness of the adjuvanted Sanofi/GSK (VidPrevtyn Beta) and Pfizer-BioNTech (Comirnaty Original/Omicron BA.4-5) bivalent vaccines against hospitalisation amongst adults aged 75 years and older in England, estimated using a test-negative case control study design

2023-09-29

Abstract excerpt

<h4>Background</h4> In England, the Joint Committee for Vaccination and Immunisation recommended a spring 2023 booster programme for all adults aged 75 years and older and the immunosuppressed. The vaccines advised were the Sanofi/GSK AS03-adjuvanted monovalent beta variant (VidPrevtyn Beta) booster vaccine and the Pfizer-BioNTech mRNA (Comirnaty Original/Omicron BA.4-5) bivalent vaccine. This is the first time an...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f3b0a38c-1064-599a-a0b9-4bc7fd1deddb
DOI
10.1101/2023.09.28.23296290
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Effectiveness of the adjuvanted Sanofi/GSK (VidPrevtyn Beta) and Pfizer-BioNTech (Comirnaty Original/Omicron BA.4-5) bivalent vaccines against hospitalisation amongst adults aged 75 years and older in England, estimated using a test-negative case control study designDOI 10.1101/2023.09.28.23296290
Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in EnglandSemantic proximity
Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation: test negative case-control studySemantic proximity
Effectiveness of BNT162b2 COVID-19 Vaccination in Prevention of Hospitalisations and Severe Disease in Adults with Delta (B.1.617.2) and Omicron (B.1.1.529) Variant SARS-CoV-2 Infection: A Prospective Test Negative Case-Control StudySemantic proximity
Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UKSemantic proximity
Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes in Ontario, Canada: a test-negative design studySemantic proximity
COVID-19 Vaccine effectiveness against symptomatic infection and hospitalization in Belgium, July 2021-APRIL 2022Semantic proximity
Duration of vaccine effectiveness against SARS-CoV2 infection, hospitalisation, and death in residents and staff of Long-Term Care Facilities (VIVALDI): a prospective cohort study, England, Dec 2020-Dec 2021Semantic proximity
Safety and effectiveness of COVID-19 mRNA vaccination and risk factors for hospitalisation caused by the omicron variant in 0.8 million adolescents: A nationwide cohort study in SwedenSemantic proximity
Effectiveness of the CoronaVac vaccine in the elderly population during a Gamma variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control studySemantic proximity
Vaccine effectiveness against hospitalisation and comparative odds of hospital admission and severe outcomes with BQ.1, CH.1.1. and XBB.1.5 in EnglandSemantic proximity
Mass testing for discovery and control of COVID-19 outbreaks in adult social care: an observational study and cost-effectiveness analysis of 14,805 care homes in EnglandSemantic proximity
Monovalent mRNA XBB.1.5 vaccine effectiveness against COVID-19 hospitalization in Quebec, Canada: impact of variant replacement and waning protection during 10-month follow-upSemantic proximity
Select a neighboring publication to make it the new centre.